The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells

  • Benigno C. Valdez, Yang Li, David Murray, Yan Liu, Yago Nieto, Richard E. Champlin, Borje S. Andersson
  • Leukemia & Lymphoma, April 2017, Taylor & Francis
  • DOI: 10.1080/10428194.2017.1306647

The authors haven't yet claimed this publication.

Read Publication

http://dx.doi.org/10.1080/10428194.2017.1306647